Aristea: Aristea begins patient dosing in phase 2a trial of RIST4721 in hidradenitis suppurativa
Aristea Therapeutics (Aristea), a clinical─stage immunology focused drug development company, announced the dosing of the first patient in its phase 2a trial evaluating RIST4721, a CXCR2 antagonist, for the
Read full article »
Aristea is a California-based biotechnology firm that develops and commercializes novel therapies for the treatment of inflammatory diseases.
Read more